Stay updated with breaking news from Lobe Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lobe Sciences Ltd. LOBEF, a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has…
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130.
As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to...
Psychedelic stocks are trading so low right now that there is no better time to invest, according to one venture capital firm. Investors have been given...
Phillips also named President of Altemia & Co., a Lobe Sciences Company ... | June 7, 2023